Caris Life Sciences (NASDAQ:CAI – Free Report) had its price objective upped by Piper Sandler from $22.00 to $25.00 in a research note released on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.
Several other analysts also recently commented on the stock. Evercore reaffirmed an “outperform” rating and set a $26.00 target price on shares of Caris Life Sciences in a report on Thursday, August 6th. Canaccord Genuity Group increased their price target on shares of Caris Life Sciences from $22.00 to $30.00 and gave the company a “hold” rating in a report on Monday, October 19th. Wall Street Zen upgraded shares of Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. TD Cowen boosted their price objective on Caris Life Sciences from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, JPMorgan Chase & Co. upped their target price on Caris Life Sciences from $25.00 to $35.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Eight equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.18.
Get Our Latest Analysis on Caris Life Sciences
Caris Life Sciences Trading Down 2.2%
Shares of Caris Life Sciences stock opened at $23.96 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.71 and a quick ratio of 5.84. The business has a fifty day simple moving average of $29.43 and a two-hundred day simple moving average of $21.72. Caris Life Sciences has a 1 year low of $14.19 and a 1 year high of $36.50. The company has a market capitalization of $6.87 billion, a price-to-earnings ratio of 74.21, a P/E/G ratio of 7.98 and a beta of 0.71.
Caris Life Sciences (NASDAQ:CAI – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. The firm had revenue of $275.36 million for the quarter. Caris Life Sciences had a net margin of 9.16% and a return on equity of 16.00%. Caris Life Sciences’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 earnings per share. Research analysts forecast that Caris Life Sciences will post 0.11 EPS for the current year.
Insider Transactions at Caris Life Sciences
In other news, insider John Russel Denton sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total value of $238,650.00. Following the completion of the sale, the insider owned 174,855 shares of the company’s stock, valued at approximately $5,563,886.10. The trade was a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the completion of the transaction, the insider owned 230,303 shares in the company, valued at $6,985,089.99. This trade represents a 63.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 1,004,712 shares of company stock valued at $27,205,419. 50.00% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in CAI. First Trust Advisors LP bought a new position in shares of Caris Life Sciences during the third quarter worth approximately $8,533,000. Ieq Capital LLC bought a new stake in shares of Caris Life Sciences in the third quarter valued at approximately $11,134,000. Focus Advisor Solutions LLC bought a new stake in shares of Caris Life Sciences in the third quarter valued at approximately $1,785,000. Voya Investment Management LLC grew its position in Caris Life Sciences by 519.8% during the third quarter. Voya Investment Management LLC now owns 72,824 shares of the company’s stock worth $2,231,000 after buying an additional 61,074 shares in the last quarter. Finally, Rothschild Investment LLC grew its position in Caris Life Sciences by 10,664.0% during the third quarter. Rothschild Investment LLC now owns 36,490 shares of the company’s stock worth $1,118,000 after buying an additional 36,151 shares in the last quarter.
Caris Life Sciences Company Profile
Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.
Further Reading
- Five stocks we like better than Caris Life Sciences
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
